Emmanuelle Charpentier and Jennifer Doudna reprogrammed the bacterial immune response into one of the most popular tools for genetics and molecular biology.

Researchers slowed disease progression in the mice by injecting two different viral vectors, each containing one part of the DNA encoding the Cas9 protein, to edit the causative gene.

In demonstrations in cell lines, the technique has a similar efficacy to CRISPR-Cas9, but fewer off-target effects.

Researchers use a CRISPR-Cas9 strategy to expand a desired trait from 50 percent of mouse pups to about 72 percent.

A mouse study details a method called VIVO that predicts the accuracy of any guide RNA.

Researchers have developed a variety of techniques to detect when CRISPR misses the mark.

A tweaked Cas9 nuclease reduces off-target effects to levels below that of previous versions of the enzyme.

In human cells, researchers deploy the genome editor to snip out toxic repetitive sequences.

Scientists correct a mutation in fertilized eggs that causes a severe cardiac disease.